JP2008535805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535805A5 JP2008535805A5 JP2008502205A JP2008502205A JP2008535805A5 JP 2008535805 A5 JP2008535805 A5 JP 2008535805A5 JP 2008502205 A JP2008502205 A JP 2008502205A JP 2008502205 A JP2008502205 A JP 2008502205A JP 2008535805 A5 JP2008535805 A5 JP 2008535805A5
- Authority
- JP
- Japan
- Prior art keywords
- ser
- leu
- gly
- ala
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66490805P | 2005-03-23 | 2005-03-23 | |
| US60/664,908 | 2005-03-23 | ||
| PCT/CA2006/000438 WO2006099739A1 (en) | 2005-03-23 | 2006-03-23 | Use of adnf polypeptides for treating peripheral neurotoxicity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535805A JP2008535805A (ja) | 2008-09-04 |
| JP2008535805A5 true JP2008535805A5 (cg-RX-API-DMAC7.html) | 2009-05-07 |
| JP5174653B2 JP5174653B2 (ja) | 2013-04-03 |
Family
ID=37023352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502205A Expired - Fee Related JP5174653B2 (ja) | 2005-03-23 | 2006-03-23 | 末梢神経毒症状を処置するためのadnfポリペプチドの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7452867B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1885389A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5174653B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006227528B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2602893A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006099739A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613740B1 (en) * | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
| US6933277B2 (en) | 1999-03-12 | 2005-08-23 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides |
| US7384908B1 (en) * | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
| US7427590B2 (en) * | 2001-09-12 | 2008-09-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Neurothrophic components of the ADNF I complex |
| US7960334B2 (en) * | 2003-03-12 | 2011-06-14 | Ramot At Tel-Aviv University Ltd. | Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia |
| JP5174653B2 (ja) * | 2005-03-23 | 2013-04-03 | ラモト アト テルーアビブ ユニバーシティー リミテッド | 末梢神経毒症状を処置するためのadnfポリペプチドの使用 |
| WO2007096859A2 (en) * | 2006-02-24 | 2007-08-30 | Ramot At Tel-Aviv University Ltd. | Protection of the retina against laser injury by adnf peptides such as nap and sal |
| WO2008084483A1 (en) | 2007-01-11 | 2008-07-17 | Ramot At Tel Aviv University Ltd. | Novel therapeutics based on tau/microtubule dynamics |
| CN101848934A (zh) * | 2007-08-24 | 2010-09-29 | 以色列特拉维夫大学拉莫特技术转移公司 | 使用nap样和sal样肽模拟物的神经保护 |
| US7998928B2 (en) * | 2007-09-14 | 2011-08-16 | The Regents Of The University Of California | Method of treatment of type-1 diabetes with a humanin analogue |
| WO2010033762A1 (en) * | 2008-09-18 | 2010-03-25 | Youssef Sari | Colivelin as a neuroprotective factor |
| US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| EP2381955A4 (en) * | 2008-12-30 | 2013-01-16 | Univ Ramot | COMBINATION THERAPIES WITH NAP |
| EP2467397A1 (en) | 2009-08-17 | 2012-06-27 | Ramot at Tel-Aviv University Ltd. | Nap alpha-aminoisobutyric acid analog with neuroprotective activity |
| WO2011032175A1 (en) | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| EP2521919B1 (en) | 2010-01-06 | 2015-03-04 | Ramot at Tel Aviv University, Ltd. | Method for diagnosing and monitoring schizophrenia and tauopathies |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| WO2017130190A1 (en) * | 2016-01-28 | 2017-08-03 | Ramot At Tel-Aviv University Ltd. | Novel formulation of neuroprotective peptides |
| EP3245944A1 (en) * | 2016-05-20 | 2017-11-22 | Institut Pasteur | Olfactory means for the diagnosis of neurological complications of nervous system infection |
| US11571396B2 (en) | 2019-03-23 | 2023-02-07 | Sandra Sermone | Ketamine for treatment of ADNP syndrome and sensory processing deficits |
| EP3979995A4 (en) | 2019-06-04 | 2023-07-26 | ADNP Kids Research Foundation | Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions |
| WO2022003673A1 (en) | 2020-06-30 | 2022-01-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Humanin analogs and uses thereof |
| US20250032580A1 (en) * | 2021-03-25 | 2025-01-30 | Ramot At Tel-Aviv University Ltd. | Use of adnf polypeptides in therapy |
| CA3213068A1 (en) | 2021-03-25 | 2022-09-29 | Ramot At Tel-Aviv University Ltd. | Compositions and articles comprising an adnf polypeptide |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740497A (en) | 1971-06-29 | 1973-06-19 | G Daniell | Artificial line bridge subscriber dial long line equipment tester |
| US4587046A (en) | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
| US5198420A (en) * | 1989-10-02 | 1993-03-30 | The General Hospital Corporation | Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome |
| US6174862B1 (en) | 1991-04-22 | 2001-01-16 | Ramot University Authority For Applied Research And Industrial Development, Ltd. | Neurotrophic peptides of activity dependent neurotrophic factor |
| US5767240A (en) | 1991-04-22 | 1998-06-16 | The United States Of America As Represented By The Department Of Health And Human Services | Activity-dependent neurotrophic factor |
| US5510264A (en) * | 1993-09-28 | 1996-04-23 | Insight Biotech Inc. | Antibodies which bind meningitis related homologous antigenic sequences |
| US6613740B1 (en) | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
| EP2172478A3 (en) * | 1997-02-07 | 2010-07-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Activity-dependent neurotrophic factor III (ADNF III) |
| US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| US6933277B2 (en) | 1999-03-12 | 2005-08-23 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides |
| US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
| US6649411B2 (en) * | 1999-07-30 | 2003-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides |
| DE60010478T2 (de) | 1999-08-18 | 2005-06-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Oral wirksame peptide, die zellschädigung und zelltod verhindern |
| US7384908B1 (en) * | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
| US7427598B2 (en) * | 2000-05-31 | 2008-09-23 | The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services | Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory |
| US20030166544A1 (en) * | 2000-09-07 | 2003-09-04 | Clark Abbot F. | Use of ADNP for the treatment of glaucomatous optic neuropathy |
| US7427590B2 (en) * | 2001-09-12 | 2008-09-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Neurothrophic components of the ADNF I complex |
| US7960334B2 (en) * | 2003-03-12 | 2011-06-14 | Ramot At Tel-Aviv University Ltd. | Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia |
| JP5174653B2 (ja) * | 2005-03-23 | 2013-04-03 | ラモト アト テルーアビブ ユニバーシティー リミテッド | 末梢神経毒症状を処置するためのadnfポリペプチドの使用 |
| WO2007096859A2 (en) * | 2006-02-24 | 2007-08-30 | Ramot At Tel-Aviv University Ltd. | Protection of the retina against laser injury by adnf peptides such as nap and sal |
| CN101848934A (zh) * | 2007-08-24 | 2010-09-29 | 以色列特拉维夫大学拉莫特技术转移公司 | 使用nap样和sal样肽模拟物的神经保护 |
-
2006
- 2006-03-23 JP JP2008502205A patent/JP5174653B2/ja not_active Expired - Fee Related
- 2006-03-23 AU AU2006227528A patent/AU2006227528B2/en not_active Ceased
- 2006-03-23 EP EP06721705A patent/EP1885389A4/en not_active Withdrawn
- 2006-03-23 WO PCT/CA2006/000438 patent/WO2006099739A1/en not_active Ceased
- 2006-03-23 CA CA002602893A patent/CA2602893A1/en not_active Abandoned
- 2006-03-23 US US11/388,634 patent/US7452867B2/en not_active Expired - Lifetime
-
2008
- 2008-10-03 US US12/245,517 patent/US8143221B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11851481B2 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g | |
| AU2017295708A1 (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| US20140322250A1 (en) | Peptides for the Treatment of Multiple Sclerosis and Related Diseases | |
| BRPI0809234A2 (pt) | Peptídeos de proteína associada a receptor (rap) cíclico | |
| JP2013533890A5 (cg-RX-API-DMAC7.html) | ||
| JP2008518026A5 (cg-RX-API-DMAC7.html) | ||
| JP2022508952A (ja) | ジルコプランによる神経疾患治療 | |
| CN104582796A (zh) | 治疗阿尔茨海默病的组合物和方法 | |
| JP2025120320A (ja) | Vipr2アンタゴニストペプチド | |
| WO2013082045A1 (en) | Netrin loop peptide mimetics and uses thereof | |
| CN102574904B (zh) | 赋予了经粘膜吸收性的胃动素样肽化合物 | |
| WO2014052766A1 (en) | Hepatocyte growth factor mimics as therapeutic agents | |
| CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
| JP4744443B2 (ja) | 毒素中和性ペプチドのスクリーニング方法とstx2阻害性ペプチド並びにベロ毒素中和剤 | |
| EP1602931A1 (en) | SR-A antagonists | |
| CN1361865A (zh) | 起催化作用的抗因子ⅷ同种抗体 | |
| JP2007515157A5 (cg-RX-API-DMAC7.html) | ||
| US20140336127A1 (en) | Stabilized Peptide Helices For Inhibiting Dimerization Of Chemokine C Motif Receptor 2 (CCR2) | |
| WO2022093684A1 (en) | Compositions and methods of treating inflammatory lung diseases | |
| TW476650B (en) | Use of a cytokine regulatory agent to treat rheumatoid arthritis | |
| WO2026094984A1 (ja) | 抗ウイルス活性を有するペプチドの塩形 | |
| KR20250028388A (ko) | 펩타이드 억제제 및 이의 용도 | |
| JP2009502797A5 (cg-RX-API-DMAC7.html) | ||
| JP6578546B2 (ja) | Lt阻害4価ペプチドおよびetec感染症治療薬 | |
| JP2619268B2 (ja) | 新規なペプチド硫酸エステル誘導体 |